Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from HC Wainwright
Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...
Cytokinetics Starts Trial For CK-586 In HFpEF
Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...
STAT9d
Cytokinetics is not looking to be acquired, CEO says
The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.
Yahoo Finance6d
Cytokinetics, Incorporated (CYTK)
PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to ...
news.stocktradersdaily1d
(CYTK) Technical Pivots with Risk Controls
Technical analysis for Cytokinetics Incorporated CYTK including support levels resistance levels and stop losses for CYTK ...
Finanznachrichten9d
Cytokinetics, Incorporated: Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030, five-year ...
Yahoo Finance10d
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...
Cytokinetics’ Innovative CK-586 Advances Bolster Buy Rating Amid HFpEF Promise
H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...